Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model

被引:0
|
作者
Roychoudhury, M [1 ]
Kulkarni, SK [1 ]
机构
[1] PANJAB UNIV,UNIV INST PHARMACEUT SCI,DIV PHARMACOL,CHANDIGARH 160014,INDIA
来源
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 1997年 / 19卷 / 02期
关键词
ondansetron; anxiety; mirrored chamber; approach-conflict; mice;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The profile of action of ondansetron ondansetron was assessed in a novel animal model of anxiety. The mirrored chamber is a nonpunishing quantitative model of anxiety which measures approach-conflict behavior. Ondansetron in all the doses tested (0.01, 0.1 and 1 mg/kg i.p.) showed significant anxiolytic action as compared to naive mice, but it was less potent as compared to a well-known anxiolytic, diazepam (1 mg/kg). These results suggest that ondansetron has anxiolytic efficacy in nonconflict paradigms of anxiety, a response not mediated by the conventional neurotransmitter receptors, GABA-benzodiazepine as flumazenil (4 mg/kg), a benzodiazepine receptor antagonist, failed to reverse the behavioral parameters evoked by ondansetron.
引用
收藏
页码:107 / 111
页数:5
相关论文
共 50 条
  • [21] 5-HT3 ANTAGONIST ONDANSETRON FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN AN OUTPATIENT POPULATION
    CASPER, J
    CASPER, S
    KOHNEWOMPNER, CH
    BOKEMEYER, C
    HECKER, H
    SCHMOLL, HJ
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 (06) : 1283 - 1289
  • [22] Long-term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT3 receptor antagonist
    King, GR
    Xiong, ZP
    Douglass, S
    Ellinwood, EH
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 394 (01) : 97 - 101
  • [23] Effect of the 5-HT3 receptor antagonist ondansetron on plasma AVP secretion: A study in cancer patients
    Barreca, T
    Corsini, G
    Cataldi, A
    Garibaldi, A
    Cianciosi, P
    Rolandi, E
    Franceschini, R
    BIOMEDICINE & PHARMACOTHERAPY, 1996, 50 (10) : 512 - 514
  • [24] EFFICACY OF ORAL ONDANSETRON, A SELECTIVE ANTAGONIST OF 5-HT3 RECEPTORS IN THE TREATMENT OF NAUSEA AND VOMITING ASSOCIATED WITH CYCLOPHOSPHAMIDE-BASED CHEMOTHERAPIES
    CUBEDDU, LX
    PENDERGRASS, K
    RYAN, T
    YORK, M
    BURTON, G
    MESHAD, M
    GALVIN, D
    CIOCIOLA, AA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (02): : 137 - 146
  • [25] Attenuation of mecamylamine-precipitated nicotine-withdrawal aversion by the 5-HT3 receptor antagonist ondansetron
    Suzuki, T
    Ise, Y
    Mori, T
    Misawa, M
    LIFE SCIENCES, 1997, 61 (16) : PL249 - PL254
  • [26] Effect of the 5-HT3 receptor antagonist, ondansetron, on gastric size in dyspeptic patients with impaired gastric accommodation
    Marzio, L.
    Cappello, G.
    Grossi, L.
    Manzoli, L.
    DIGESTIVE AND LIVER DISEASE, 2008, 40 (03) : 188 - 193
  • [27] 5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway
    Shinohara, Motoko
    Shinohara, Mitsuru
    Zhao, Jing
    Fu, Yuan
    Liu, Chia-Chen
    Kanekiyo, Takahisa
    Bu, Guojun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (06):
  • [28] Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds
    Faris, PL
    Kim, SW
    Meller, WH
    Goodale, RL
    Hofbauer, RD
    Oakman, SA
    Howard, LA
    Stevens, ER
    Eckert, ED
    Hartman, BK
    PAIN, 1998, 77 (03) : 297 - 303
  • [29] Influence of the 5-HT3 receptor antagonist ondansetron on gastric sensorimotor function and nutrient tolerance in healthy volunteers
    Janssen, P.
    Vos, R.
    Van Oudenhove, L.
    Tack, J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 (05) : 444 - e175
  • [30] PHARMACOLOGICAL CHARACTERIZATION OF RS-25259-197, A NOVEL AND SELECTIVE 5-HT3 RECEPTOR ANTAGONIST, IN-VIVO
    EGLEN, RM
    LEE, CH
    SMITH, WL
    JOHNSON, LG
    CLARK, R
    WHITING, RL
    HEGDE, SS
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (04) : 860 - 866